A carregar...
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
BACKGROUND: The high cost and prolonged timeline of new drug discovery and development are major roadblocks to creating therapies for infectious diseases. Candida albicans is an opportunistic fungal pathogen that is the most common cause of fatal fungal infections in humans and costs $2–4 billion do...
Na minha lista:
| Publicado no: | Ann Clin Microbiol Antimicrob |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4462072/ https://ncbi.nlm.nih.gov/pubmed/26054754 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12941-015-0090-4 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|